Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Study Summary

Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.

Conditions

Small Cell Lung Cancer

Interventions / Drugs

Pembrolizumab 200 mg Pembrolizumab 400 mg Pembrolizumab placebo (saline)Pembrolizumab placebo (saline)Olaparib 300 mg BID Olaparib matching placebo Etoposide 100 mg/m^2 Platinum, investigator's choice Standard Thoracic Radiotherapy Prophylactic Cranial Irradiation (PCI)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment672 participants

Primary Completion—

Lead SponsorMerck Sharp & Dohme LLC

Data Retrieved2026-04-11 02:55:36.204655+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.